Señales en vivo de FUSN | Maximiza tus Ganancias con Getagraph.com

VENDER 118727 min ago

@ $11.17

Emitido: 14 feb 2024 @ 15:35

Retorno: 91.76%

Señal anterior: feb 14 - 14:36

Señal anterior: Comprar

Retorno: 1.92 %

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 16:00):

Stats
Volumen de hoy	255 114
Volumen promedio	2.11M
Capitalización de mercado	1.82B
EPS	$-0.390 ( 2024-03-21 )
Próxima fecha de ganancias	( $-0.370 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.77
ATR14	$0.00500 (0.02%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-04	Leamon Christopher P	Buy	106 100	Stock Option (Right to Buy)
2024-01-04	Leamon Christopher P	Buy	63 700	Restricted Stock Units
2023-08-31	Leamon Christopher P	Buy	11 957	Common Stock
2024-01-04	Crowley John J	Buy	106 100	Stock Option (Right to Buy)
2024-01-04	Crowley John J	Buy	63 700	Restricted Stock Units

INSIDER POWER
100.00
Last 91 transactions
Buy: 6 470 725 \| Sell: 164 236

Volumen Correlación

Largo: -0.26 (neutral)

Corto: 0.18 (neutral)

Signal:(35.062) Neutral

Fusion Pharmaceuticals Correlación

10 Correlaciones Más Positivas
QADB	0.977
CMPI	0.965
ALBO	0.952
JNCE	0.945
EBACU	0.945
TZPS	0.932
MCAA	0.931
DXPE	0.927
ARTEU	0.926
IVCB	0.924

10 Correlaciones Más Negativas
RGF	-0.951
IMRX	-0.943
ORPH	-0.942
PRTS	-0.939
ATAK	-0.937
NDLS	-0.934
MTEM	-0.934
RGC	-0.932
RMGC	-0.928
WKSP	-0.927

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Fusion Pharmaceuticals Correlación - Moneda/Commodity

0.56
( weak )

0.26
( neutral )

0.00
( neutral )

0.77
( moderate )

Fusion Pharmaceuticals Finanzas

Annual	2023
Ingresos:	$2.07M
Beneficio Bruto:	$723 000 (34.96 %)
EPS:	$-1.450

FY	2023
Ingresos:	$2.07M
Beneficio Bruto:	$723 000 (34.96 %)
EPS:	$-1.450

FY	2022
Ingresos:	$1.46M
Beneficio Bruto:	$-57.43M (-3 931.14 %)
EPS:	$-2.00

FY	2021
Ingresos:	$1.44M
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.884

Financial Reports:

No articles found.

Fusion Pharmaceuticals

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.

Actualizaciones en tiempo real para Fusion Pharmaceuticals [FUSN]

Upcoming Earnings Alert